Fund moves
89 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 18, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 25, 2025 · Filed Nov 25, 2025
Abbott Laboratories's Senior Vice President sold $203K of Abbott Laboratories shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$203,043
Shares × reported transaction price
41 days after results of Oct 15, 2025, 58 days before results of Jan 22, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $128.05 on Nov 25, 2025, 15% above its 52-week low and 9% below its high, after a 4% drop over the previous 30 trading days
52-week range $111.10 (Jan 15, 2025) to $140.22 (Mar 3, 2025), 58% of the way up, from 250 adjusted closes. 30 trading days earlier: $133.27 on Oct 14, 2025. Describes the past only, not a forecast
RSI 51, 2% under its 200-day average, 1% under its 50-day average, 9% below the 52-week high, 20-day volatility 22% a year, against the S&P 500: +2 points over 1 month, −7 points over 3 months, −18 points over 6 months
From the adjusted closes up to Nov 25, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Volt PFA System on Dec 19, 2025, 24 days after this trade.
Premarket approval (PMA): Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.5% | +0.6% | −3.1% |
| 30 days | −2.9% | +1.6% | −4.4% |
| 90 days | −10.9% | +1.1% | −12.0% |
| 180 days | −32.6% | +10.4% | −43.0% |
Past results only. Not a forecast.
Fund moves
89 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 18, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Congress
Traded Nov 18, 2025 · disclosed 27 days later
7 different filers disclosed ABT within 90 days.
Insider filing
Traded Dec 11, 2025 · filed 1 day later
Gift or transfer — classified separately from trades.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.